Assure Tech Hangzhou Co Ltd - Asset Resilience Ratio
Assure Tech Hangzhou Co Ltd (688075) has an Asset Resilience Ratio of 23.61% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Assure Tech Hangzhou Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Assure Tech Hangzhou Co Ltd's Asset Resilience Ratio has changed over time. See Assure Tech Hangzhou Co Ltd (688075) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Assure Tech Hangzhou Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688075 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.33 Billion | 23.61% |
| Total Liquid Assets | CN¥1.33 Billion | 23.61% |
Asset Resilience Insights
- Good Liquidity Position: Assure Tech Hangzhou Co Ltd maintains a healthy 23.61% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Assure Tech Hangzhou Co Ltd Industry Peers by Asset Resilience Ratio
Compare Assure Tech Hangzhou Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 30.29% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Shanghai Junshi Biosciences Co Ltd
SHG:688180 |
Biotechnology | 4.28% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 83.49% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 41.74% |
Annual Asset Resilience Ratio for Assure Tech Hangzhou Co Ltd (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Assure Tech Hangzhou Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 26.62% | CN¥1.54 Billion ≈ $224.77 Million |
CN¥5.77 Billion ≈ $844.23 Million |
-3.57pp |
| 2023-12-31 | 30.19% | CN¥1.75 Billion ≈ $255.80 Million |
CN¥5.79 Billion ≈ $847.19 Million |
+9.94pp |
| 2022-12-31 | 20.25% | CN¥1.41 Billion ≈ $205.74 Million |
CN¥6.94 Billion ≈ $1.02 Billion |
+20.25pp |
| 2021-12-31 | 0.00% | CN¥144.87K ≈ $21.20K |
CN¥3.28 Billion ≈ $480.03 Million |
-- |
About Assure Tech Hangzhou Co Ltd
Assure Tech (Hangzhou) Co., Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents, and instruments in China. It is also involved in POCT and plastic product manufacturing; online sales; pharmaceutical sales; and medical testing. In addition, the company offers drug of abuse, infectious disease, fertility, cardiac marker, tumor marker, allergen, and veteri… Read more